Lipella Pharmaceuticals Inc
OTC:LIPO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lipella Pharmaceuticals Inc
OTC:LIPO
|
US |
|
Tali Digital Ltd
ASX:TD1
|
AU |
|
L
|
Live Energy Minerals Corp
CNSX:LIVE
|
CA |
|
I
|
IC Capitalight Corp
CNSX:IC
|
CA |
|
B
|
BrainAurora Medical Technology Ltd
HKEX:6681
|
CN |
|
G
|
Guangzhou Rural Commercial Bank Co Ltd
HKEX:1551
|
CN |
|
BAE Systems PLC
LSE:BA
|
UK |
Lipella Pharmaceuticals Inc
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10 and LP-310. LP-10 is its proprietary formulation of tacrolimus and is optimized for local delivery to the urinary bladder. LP-310, another proprietary formulation of tacrolimus, is optimized for delivery to the oral mucosa (the tissue lining the walls inside the mouth) and tongue surface. The company is developing LP-310 for the treatment of oral lichen planus (OLP), a chronic inflammatory condition affecting the mucous membranes inside the mouth. The company has developed a proprietary technology, referred to as its Platform, which is optimized for local hydrophobic drug delivery to body cavities having endothelial surfaces. Its Platform includes proprietary drug delivery technologies optimized for use with epithelial tissues.
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10 and LP-310. LP-10 is its proprietary formulation of tacrolimus and is optimized for local delivery to the urinary bladder. LP-310, another proprietary formulation of tacrolimus, is optimized for delivery to the oral mucosa (the tissue lining the walls inside the mouth) and tongue surface. The company is developing LP-310 for the treatment of oral lichen planus (OLP), a chronic inflammatory condition affecting the mucous membranes inside the mouth. The company has developed a proprietary technology, referred to as its Platform, which is optimized for local hydrophobic drug delivery to body cavities having endothelial surfaces. Its Platform includes proprietary drug delivery technologies optimized for use with epithelial tissues.
